However, studies in RCC have determined that detectable tumor expression of PD-L1 can be documented only in a small fraction of patients (20–30%), yet, a higher number of patients with PD-L1 negative RCC responded to PD-1 blockade (194). Here, PDCD1 is linked to neoplasm.